LifeMD is trading at $3.13, with a -5.00% change, alongside a weaker market as the S&P 500, Nasdaq Composite, and Dow Jones are all lower.
- No clear company-specific negative announcement was identified for September 23, 2026; the latest company news was a preferred-stock dividend declaration.
- H.C. Wainwright maintained its Buy rating and $9 target.
- Rising crude oil and Treasury yields are reinforcing broader risk-off pressure.